All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub is happy to present a Visual Abstract summarizing key data from the phase III QuANTUM-First trial, evaluating the addition of quizartinib vs placebo to standard chemotherapy and up to three years of continuation therapy in adults aged 18–75 with newly diagnosed FLT3-ITD+ acute myeloid leukemia (AML).
Download this visual abstract
Click here to download this visual abstractDownload
Triplet combination of HMA, FLT3 inhibitors, and venetoclax in FLT3-mutated newly diagnosed AML
This study suggests that in older/unfit adult patients with newly diagnosed AML the triplet combination of HMA, FLT3 inhibitor, and venetoclax is...
Targeted therapy for FLT3 mutated AML - Educational session at the 2017 ASCO Annual Meeting
An Educational Session took place during the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting discussing emerging treatment options for Acute...
Subscribe to get the best content related to AML delivered to your inbox